Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma

Regulatory Peptides

Volumn 165, Issue 1, 2010, Pages 21-29

  Guérin, Marlène ^a   Guillemot, Johann ^a   Thouënnon, Erwan ^a   Pierre, Alice ^a   El Yamani, Fatima Zohra ^b   Montero Hadjadje, Maité ^a   Dubessy, Christophe ^a   Magoul, Rabia ^b   Lihrmann, Isabelle ^a   Anouar, Youssef ^a   Yon, Laurent ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b Université Sidi Mohammed Ben Abdellah   (Morocco)

Author keywords

Chromaffin tumor; Chromogranin; Neuroendocrine tumor; Paraganglioma; Pheochromocytoma; Secretogranin

Indexed keywords

CHROMACIN; CHROMOGRANIN A; CHROMOGRANIN A [402-436]; CHROMOGRANIN B; CHROMOGRANIN B [420-493]; CLONIDINE; METOPROLOL; NEUROPEPTIDE; PANCREASTATIN; PEPTIDE WE 14; PHENTOLAMINE; SECRETOGRANIN II; SECRETOGRANIN II [187-252]; SECRETOGRANIN III; SECRETOGRANIN IV; SECRETOGRANIN V; SECRETOGRANIN VI; SECRETOGRANIN VII; SECRETONEURIN; SECRETORY PROTEIN; TYRAMINE; UNCLASSIFIED DRUG;

CATECHOLAMINE RELEASE; CHROMAFFIN SYSTEM; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOREACTIVITY; NONHUMAN; PEPTIDE ANALYSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; CHROMAFFIN CELLS; CHROMOGRANINS; HUMANS; PHEOCHROMOCYTOMA;

EID: 78649882036     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.06.003     Document Type: Review

References (122)

1. Rosa P., Gerdes H.H. The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest 1994, 17:207-225.
2. Fischer-Colbrie R., Laslop A., Kirchmair R. Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 1995, 46:49-70.
3. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25years and future perspectives. Neuroscience 1992, 49:497-528.
4. Steiner H.J., Weiler R., Ludescher C., Schmid K.W., Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 1990, 38:845-850.
5. Tasiemski A., Hammad H., Vandenbulcke F., Breton C., Bilfinger T.J., Pestel J., Salzet M. Presence of chromogranin-derived antimicrobial peptides in plasma during coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002, 100:553-559.
6. Saruta J., Tsukinoki K., Sasaguri K., Ishii H., Yasuda M., Osamura Y.R., Watanabe Y., Sato S. Expression and localization of chromogranin A gene and protein in human submandibular gland. Cells Tissues Organs 2005, 180:237-244.
7. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 2003, 348:1134-1149.
8. Helle K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004, 79:769-794.
9. Banks P., Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965, 97:40C-41C.
10. Lee R.W., Huttner W.B. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983, 258:11326-11334.
11. Rosa P., Hille A., Lee R.W., Zanini A., De Camilli P., Huttner W.B. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985, 101:1999-2011.
12. Ottiger H.P., Battenberg E.F., Tsou A.P., Bloom F.E., Sutcliffe J.G. 1B1075: a brain- and pituitary-specific mRNA that encodes a novel chromogranin/secretogranin-like component of intracellular vesicles. J Neurosci 1990, 10:3135-3147.
13. Krisch K., Buxbaum P., Horvat G., Krisch I., Neuhold N., Ulrich W., Srikanta S. Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation. Its application in diagnostic pathology. Am J Pathol 1986, 123:100-108.
14. Iguchi H., Chan J.S., Seidah N.G., Chretien M. Tissue distribution and molecular forms of a novel pituitary protein in the rat. Neuroendocrinology 1984, 39:453-458.
15. Ischia R., Lovisetti-Scamihorn P., Hogue-Angeletti R., Wolkersdorfer M., Winkler H., Fischer-Colbrie R. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J Biol Chem 1997, 272:11657-11662.
16. Levi A., Eldridge J.D., Paterson B.M. Molecular cloning of a gene sequence regulated by nerve growth factor. Science 1985, 229:393-395.
17. Fricker L.D., McKinzie A.A., Sun J., Curran E., Qian Y., Yan L., Patterson S.D., Courchesne P.L., Richards B., Levin N., Mzhavia N., Devi L.A., Douglass J. Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. J Neurosci 2000, 20:639-648.
18. Chanat E., Huttner W.B. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991, 115:1505-1519.
19. Iacangelo A.L., Eiden L.E. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995, 58:65-88.
20. Kim T., Tao-Cheng J.H., Eiden L.E., Loh Y.P. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 2001, 106:499-509.
21. Montero-Hadjadje M., Vaingankar S., Elias S., Tostivint H., Mahata S.K., Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) 2008, 192:309-324.
22. Zhao E., Zhang D., Basak A., Trudeau V.L. New insights into granin-derived peptides: evolution and endocrine roles. Gen Comp Endocrinol 2009, 164:161-174.
23. Ferrari L., Seregni E., Bajetta E., Martinetti A., Bombardieri E. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 1999, 19:3415-3427.
24. Kimura N., Miura W., Noshiro T., Mizunashi K., Hanew K., Shimizu K., Watanabe T., Shibukawa S., Sohn H.E., Abe K., Miura Y., Nagura H. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J 1997, 44:319-327.
25. Thouënnon E., Elkahloun A.G., Guillemot J., Gimenez-Roqueplo A.P., Bertherat J., Pierre A., Ghzili H., Grumolato L., Muresan M., Klein M., Lefebvre H., Ouafik L., Vaudry H., Plouin P.F., Yon L., Anouar Y. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 2007, 92:4865-4872.
26. Burnichon N., Rohmer V., Amar L., Herman P., Leboulleux S., Darrouzet V., Niccoli P., Gaillard D., Chabrier G., Chabolle F., Coupier I., Thieblot P., Lecomte P., Bertherat J., Wion-Barbot N., Murat A., Venisse A., Plouin P.F., Jeunemaitre X., Gimenez-Roqueplo A.P. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009, 94:2817-2827.
27. Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma. Lancet 2005, 366:665-675.
28. Scholz T., Schulz C., Klose S., Lehnert H. Diagnostic management of benign and malignant pheochromocytoma. Exp Clin Endocrinol Diab 2007, 115:155-159.
29. O'Connor D.T. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept 1983, 6:263-280.
30. O'Connor D.T., Burton D., Deftos L.J. Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci 1983, 33:1657-1663.
31. O'Connor D.T., Burton D., Deftos L.J. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 1983, 57:1084-1086.
32. O'Connor D.T., Bernstein K.N. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984, 311:764-770.
33. Dillen L., De Block J., Van Lear L., De Potter W. Enzyme-linked immunosorbent assay for chromogranin A. Clin Chem 1989, 35:1934-1938.
34. Degorce F., Goumon Y., Jacquemart L., Vidaud C., Bellanger L., Pons-Anicet D., Seguin P., Metz-Boutigue M.H., Aunis D. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 1999, 79:65-71.
35. Cleary S., Phillips J.K., Huynh T.T., Pacak K., Fliedner S., Elkahloun A.G., Munson P., Worrell R.A., Eisenhofer G. Chromogranin A expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Horm Metab Res 2007, 39:876-883.
36. Hsiao R.J., Parmer R.J., Takiyyuddin M.A., O'Connor D.T. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991, 70:33-45.
37. Hsiao R.J., Neumann H.P., Parmer R.J., Barbosa J.A., O'Connor D.T. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 1990, 88:607-613.
38. Nobels F.R., Kwekkeboom D.J., Coopmans W., Schoenmakers C.H., Lindemans J., De Herder W.W., Krenning E.P., Bouillon R., Lamberts S.W. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622-2628.
39. Boomsma F., Bhaggoe U.M., Man in 't Veld A.J., Schalekamp M.A. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta 1995, 239:57-63.
40. Stridsberg M., Husebye E.S. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997, 136:67-73.
41. Giovanella L., Ceriani L. Serum chromogranin-alpha immunoradiometric assay in the diagnosis of pheochromocytoma. Int J Biol Markers 2002, 17:130-134.
42. d'Herbomez M., Gouze V., Huglo D., Nocaudie M., Pattou F., Proye C., Wemeau J.L., Marchandise X. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. J Nucl Med 2001, 42:993-997.
43. d'Herbomez M., Forzy G., Bauters C., Tierny C., Pigny P., Carnaille B., Pattou F., Wemeau J.L., Rouaix N. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007, 156:569-575.
44. Giovanella L., Squin N., Ghelfo A., Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 2006, 50:344-347.
45. Grossrubatscher E., Dalino P., Vignati F., Gambacorta M., Pugliese R., Boniardi M., Rossetti O., Marocchi A., Bertuzzi M., Loli P. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 2006, 65:287-293.
46. Bravo E.L. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994, 15:356-368.
47. Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003, 24:539-553.
48. Algeciras-Schimnich A., Preissner C.M., Young W.F., Singh R.J., Grebe S.K. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008, 93:91-95.
49. Canale M.P., Bravo E.L. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994, 78:1139-1144.
50. Stridsberg M., Oberg K., Li Q., Engstrom U., Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995, 144:49-59.
51. Sanduleanu S., De Bruine A., Stridsberg M., Jonkers D., Biemond I., Hameeteman W., Lundqvist G., Stockbrugger R.W. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001, 31:802-811.
52. Igaz P., Mullner K., Hargitai B., Igaz I., Tombol Z., Racz K., Tulassay Z. Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy. Clin Endocrinol (Oxf) 2007, 67:805-806.
53. Borch K., Stridsberg M., Burman P., Rehfeld J.F. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997, 32:198-202.
54. Spadaro A., Ajello A., Morace C., Zirilli A., D'Arrigo G., Luigiano C., Martino F., Bene A., Migliorato D., Turiano S., Ferrau O., Freni M.A. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 2005, 11:1987-1990.
55. Stridsberg M., Eriksson B., Oberg K., Janson E.T. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003, 177:337-341.
56. Bilek R., Safarik L., Ciprova V., Vlcek P., Lisa L. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res 2008, 57:S171-S179.
57. Stridsberg M., Eriksson B., Fellstrom B., Kristiansson G., Tiensuu Janson E. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept 2007, 139:80-83.
58. Cotesta D., Caliumi C., Alo P., Petramala L., Reale M.G., Masciangelo R., Signore A., Cianci R., D'Erasmo E., Letizia C. High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori 2005, 91:53-58.
59. Rao F., Keiser H.R., O'Connor D.T. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 2000, 36:1045-1052.
60. Thompson L.D. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002, 26:551-566.
61. Portela-Gomes G.M., Grimelius L., Johansson H., Wilander E., Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am J Surg Pathol 2001, 25:1261-1267.
62. Curry W.J., Shaw C., Johnston C.F., Thim L., Buchanan K.D. Isolation and primary structure of a novel chromogranin A-derived peptide, WE-14, from a human midgut carcinoid tumour. FEBS Lett 1992, 301:319-321.
63. Conlon J.M., Hamberger B., Grimelius L. Isolation of peptides arising from the specific posttranslational processing of chromogranin A and chromogranin B from human pheochromocytoma tissue. Peptides 1992, 13:639-644.
64. Gleeson C.M., Curry W.J., Johnston C.F., Buchanan K.D. Occurrence of WE-14 and chromogranin A-derived peptides in tissues of the human and bovine gastro-entero-pancreatic system and in human neuroendocrine neoplasia. J Endocrinol 1996, 151:409-420.
65. Montero-Hadjadje M., Vaudry H., Turquier V., Leprince J., Do Rego J.L., Yon L., Gallo-Payet N., Plouin P.F., Anouar Y. Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands. Cell Tissue Res 2002, 310:223-236.
66. Anouar Y., Yon L., Guillemot J., Thouënnon E., Barbier L., Gimenez-Roqueplo A.P., Bertherat J., Lefebvre H., Klein M., Muresan M., Grouzmann E., Plouin P.F., Vaudry H., Elkahloun A.G. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Ann NY Acad Sci 2006, 1073:533-540.
67. Guillemot J., Compagnon P., Cartier D., Thouënnon E., Bastard C., Lihrmann I., Pichon P., Thuillez C., Plouin P.F., Bertherat J., Anouar Y., Kuhn J.M., Yon L., Lefebvre H. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer 2009, 16:281-290.
68. Bishop A.E., Bretherton-Watt D., Hamid Q.A., Fahey M., Shepherd N., Valentino K., Tatemoto K., Ghatei M.A., Bloom S.R., Polak J.M. The occurrence of pancreastatin in tumours of the diffuse neuroendocrine system. Mol Cell Probes 1988, 2:225-235.
69. Benedum U.M., Lamouroux A., Konecki D.S., Rosa P., Hille A., Baeuerle P.A., Frank R., Lottspeich F., Mallet J., Huttner W.B. The primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. EMBO J 1987, 6:1203-1211.
70. Fischer-Colbrie R., Lassmann H., Hagn C., Winkler H. Immunological studies on the distribution of chromogranin A and B in endocrine and nervous tissues. Neuroscience 1985, 16:547-555.
71. Hagn C., Schmid K.W., Fischer-Colbrie R., Winkler H. Chromogranin A, B, and C in human adrenal medulla and endocrine tissues. Lab Invest 1986, 55:405-411.
72. Lloyd R.V., Cano M., Rosa P., Hille A., Huttner W.B. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. Am J Pathol 1988, 130:296-304.
73. Weiler R., Fischer-Colbrie R., Schmid K.W., Feichtinger H., Bussolati G., Grimelius L., Krisch K., Kerl H., O'Connor D., Winkler H. Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol 1988, 12:877-884.
74. Portela-Gomes G.M., Stridsberg M., Grimelius L., Falkmer U.G., Falkmer S. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas. An immunohistochemical study with region-specific antibodies. APMIS 2004, 112:663-673.
75. Benjannet S., Leduc R., Lazure C., Seidah N.G., Marcinkiewicz M., Chretien M. GAWK, a novel human pituitary polypeptide: isolation, immunocytochemical localization and complete amino acid sequence. Biochem Biophys Res Commun 1985, 126:602-609.
76. Benjannet S., Leduc R., Adrouche N., Falgueyret J.P., Marcinkiewicz M., Seidah N.G., Mbikay M., Lazure C., Chretien M. Chromogranin B (secretogranin I), a putative precursor of two novel pituitary peptides through processing at paired basic residues. FEBS Lett 1987, 224:142-148.
77. Bishop A.E., Sekiya K., Salahuddin M.J., Carlei F., Rindi G., Fahey M., Steel J.H., Hedges M., Domoto T., Fischer-Colbrie R., Winkler H., Krausz T., Ghatei M.A., Bloom S.R., Polak J.M. The distribution of GAWK-like immunoreactivity in neuroendocrine cells of the human gut, pancreas, adrenal and pituitary glands and its co-localisation with chromogranin B. Histochemistry 1989, 90:475-483.
78. Sekiya K., Ghatei M.A., Salahuddin M.J., Bishop A.E., Hamid Q.A., Ibayashi H., Polak J.M., Bloom S.R. Production of GAWK (chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest 1989, 83:1834-1842.
79. Schober M., Fischer-Colbrie R., Schmid K.W., Bussolati G., O'Connor D.T., Winkler H. Comparison of chromogranins A, B, and secretogranin II in human adrenal medulla and pheochromocytoma. Lab Invest 1987, 57:385-391.
80. Guillemot J., Barbier L., Thouënnon E., Vallet-Erdtmann V., Montero-Hadjadje M., Lefebvre H., Klein M., Muresan M., Plouin P.F., Seidah N., Vaudry H., Anouar Y., Yon L. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas. Ann NY Acad Sci 2006, 1073:527-532.
81. Stridsberg M., Eriksson B., Janson E.T. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept 2008, 148:95-98.
82. Wiedermann C.J. Secretoneurin: a functional neuropeptide in health and disease. Peptides 2000, 21:1289-1298.
83. Fischer-Colbrie R., Kirchmair R., Kähler C.M., Wiedermann C.J., Saria A. Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr Protein Pept Sci 2005, 6:373-385.
84. Kirchmair R., Hogue-Angeletti R., Gutierrez J., Fischer-Colbrie R., Winkler H. Secretoneurin-a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience 1993, 53:359-365.
85. Schmid K.W., Kunk B., Kirchmair R., Totsch M., Bocker W., Fischer-Colbrie R. Immunohistochemical detection of secretoneurin, a novel neuropeptide endoproteolytically processed from secretogranin II, in normal human endocrine and neuronal tissues. Histochem J 1995, 27:473-481.
86. Ischia R., Gasser R.W., Fischer-Colbrie R., Eder U., Pagani A., Cubeddu L.X., Lovisetti-Scamihorn P., Finkenstedt G., Laslop A., Winkler H. Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab 2000, 85:355-360.
87. Anouar Y., Jegou S., Alexandre D., Lihrmann I., Conlon J.M., Vaudry H. Molecular cloning of frog secretogranin II reveals the occurrence of several highly conserved potential regulatory peptides. FEBS Lett 1996, 394:295-299.
88. Anouar Y., Desmoucelles C., Yon L., Leprince J., Breault L., Gallo-Payet N., Vaudry H. Identification of a novel secretogranin II-derived peptide (SgII(187-252)) in adult and fetal human adrenal glands using antibodies raised against the human recombinant peptide. J Clin Endocrinol Metab 1998, 83:2944-2951.
89. Montero-Hadjadje M., Pelletier G., Yon L., Li S., Guillemot J., Magoul R., Tillet Y., Vaudry H., Anouar Y. Biochemical characterization and immunocytochemical localization of EM66, a novel peptide derived from secretogranin II, in the rat pituitary and adrenal glands. J Histochem Cytochem 2003, 51:1083-1095.
90. Guillemot J., Aït-Ali D., Turquier V., Montero-Hadjadje M., Fournier A., Vaudry H., Anouar Y., Yon L. Involvement of multiple signaling pathways in PACAP-induced EM66 secretion from chromaffin cells. Regul Pept 2006, 137:79-88.
91. Yon L., Guillemot J., Montero-Hadjadje M., Grumolato L., Leprince J., Lefebvre H., Contesse V., Plouin P.F., Vaudry H., Anouar Y. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J Clin Endocrinol Metab 2003, 88:2579-2585.
92. Guillemot J., Anouar Y., Montero-Hadjadje M., Grouzmann E., Grumolato L., Roshmaninho-Salgado J., Turquier V., Duparc C., Lefebvre H., Plouin P.F., Klein M., Muresan M., Chow B.K., Vaudry H., Yon L. Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma. Int J Cancer 2006, 118:2003-2012.
93. Buffa R., Pelagi M., Siccardi A.G., Curzio M., Yu J.Y., Bordi C. Identification of the endocrine cells detected by the monoclonal antibody HISL-19 in human tissues. Basic Appl Histochem 1990, 34:259-268.
94. Shimizu K., Namimatsu S., Kitagawa W., Akasu H., Takatsu K., Sugisaki Y., Tanaka S. Immunohistochemical, biochemical and immunoelectron microscopic analysis of antigenic proteins on neuroendocrine cell tumors using monoclonal antibody HISL-19. J Nippon Med Sch 2002, 69:365-372.
95. Iguchi H., Natori S., Nawata H., Kato K., Ibayashi H., Chan J.S., Seidah N.G., Chretien M. Presence of the novel pituitary protein "7B2" in bovine chromaffin granules: possible co-release of 7B2 and catecholamine as induced by nicotine. J Neurochem 1987, 49:1810-1814.
96. Brayton K.A., Aimi J., Qiu H., Yazdanparast R., Ghatei M.A., Polak J.M., Bloom S.R., Dixon J.E. Cloning, characterization, and sequence of a porcine cDNA encoding a secreted neuronal and endocrine protein. DNA 1988, 7:713-719.
97. Marcinkiewicz M., Benjannet S., Falgueyret J.P., Seidah N.G., Schurch W., Verdy M., Cantin M., Chretien M. Identification and localization of 7B2 protein in human, porcine, and rat thyroid gland and in human medullary carcinoma. Endocrinology 1988, 123:866-873.
98. Hacker G.W., Bishop A.E., Terenghi G., Varndell I.M., Aghahowa J., Pollard K., Thurner J., Polak J.M. Multiple peptide production and presence of general neuroendocrine markers detected in 12 cases of human phaeochromocytoma and in mammalian adrenal glands. Virchows Arch Pathol Anat Histopathol 1988, 412:399-411.
99. Vieau D., Linard C.G., Mbikay M., Lenne F., Chretien M., Luton J.P., Bertagna X. Expression of the neuroendocrine cell marker 7B2 in human ACTH secreting tumours. Clin Endocrinol 1992, 36:597-603.
100. Natori S., Iguchi H., Ohashi M., Nawata H. Plasma 7B2 (a novel pituitary protein) immunoreactivity concentrations in patients with various endocrine disorders. Endocrinol Jpn 1988, 35:651-654.
101. Fischer-Colbrie R., Eder S., Lovisetti-Scamihorn P., Becker A., Laslop A. Neuroendocrine secretory protein 55: a novel marker for the constitutive secretory pathway. Ann NY Acad Sci 2002, 971:317-322.
102. Bauer R., Weiss C., Marksteiner J., Doblinger A., Fischer-Colbrie R., Laslop A. The new chromogranin-like protein NESP55 is preferentially localized in adrenaline-synthesizing cells of the bovine and rat adrenal medulla. Neurosci Lett 1999, 263:13-16.
103. Jakobsen A.M., Ahlman H., Kolby L., Abrahamsson J., Fischer-Colbrie R., Nilsson O. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids. Br J Cancer 2003, 88:1746-1754.
104. Nilsson O., Jakobsen A.M., Kolby L., Bernhardt P., Forssell-Aronsson E., Ahlman H. Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann NY Acad Sci 2004, 1014:280-283.
105. Srivastava A., Padilla O., Fischer-Colbrie R., Tischler A.S., Dayal Y. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol 2004, 28:1371-1378.
106. Mzhavia N., Qian Y., Feng Y., Che F.Y., Devi L.A., Fricker L.D. Processing of proSAAS in neuroendocrine cell lines. Biochem J 2002, 361:67-76.
107. Chakraborty T.R., Tkalych O., Nanno D., Garcia A.L., Devi L.A., Salton S.R. Quantification of VGF- and pro-SAAS-derived peptides in endocrine tissues and the brain, and their regulation by diet and cold stress. Brain Res 2006, 1089:21-32.
108. Rindi G., Licini L., Necchi V., Bottarelli L., Campanini N., Azzoni C., Favret M., Giordano G., D'Amato F., Brancia C., Solcia E., Ferri G.L. Peptide products of the neurotrophin-inducible gene vgf are produced in human neuroendocrine cells from early development and increase in hyperplasia and neoplasia. J Clin Endocrinol Metab 2007, 92:2811-2815.
109. Feng Y., Reznik S.E., Fricker L.D. Distribution of proSAAS-derived peptides in rat neuroendocrine tissues. Neuroscience 2001, 105:469-478.
110. Tischler A.S. Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas. Endocr Pathol 2006, 17:321-328.
111. Pacak K., Eisenhofer G. An assessment of biochemical tests for the diagnosis of pheochromocytoma. Nat Clin Pract Endocrinol Metab 2007, 3:744-745.
112. Gao B., Meng F., Bian W., Chen J., Zhao H., Ma G., Shi B., Zhang J., Liu Y., Xu Z. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 2006, 68:282-286.
113. Strong V.E., Kennedy T., Al-Ahmadie H., Tang L., Coleman J., Fong Y., Brennan M., Ghossein R.A. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008, 143:759-768.
114. Brouwers F.M., Elkahloun A.G., Munson P.J., Eisenhofer G., Barb J., Linehan W.M., Lenders J.W., De Krijger R., Mannelli M., Udelsman R., Ocal I.T., Shulkin B.L., Bornstein S.R., Breza J., Ksinantova L., Pacak K. Gene expression profiling of benign and malignant pheochromocytoma. Ann NY Acad Sci 2006, 1073:541-556.
115. Eisenhofer G., Goldstein D.S., Sullivan P., Csako G., Brouwers F.M., Lai E.W., Adams K.T., Pacak K. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005, 90:2068-2075.
116. Thouënnon E., Pierre A., Guillemot J., Yon L., Eisenhofer G., Anouar Y. Genetic markers for the diagnosis and prognosis of pheochromocytoma. Expert Rev Endocrinol Metab 2009, 4:45-52.
117. Neumann H.P. Imaging vs biochemical testing for pheochromocytoma. Jama 2002, 288:314-315.
118. Sawka A.M., Gafni A., Thabane L., Young W.F. The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 2004, 89:2859-2866.
119. Tischler A.S. Pheochromocytoma and extra-adrenal paraganglioma. Updates. Arch Pathol Lab Med. 2008, 132:1272-1284.
120. Kimura N., Watanabe T., Noshiro T., Shizawa S., Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 2005, 16:23-32.
121. Bílek R., Safarík L., Ciprová V., Vlcek P., Lisá L. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res 2008, 57:S171-S179.
122. Colombo B., Curnis F., Foglieni C., Monno A., Arrigoni G., Corti A. Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res 2002, 62:941-946.